Novel Microcrystal Formulations of Sorafenib Facilitate a Long-Acting Antitumor Effect and Relieve Treatment Side Effects as Observed With Fundus Microcirculation Imaging

Novel Microcrystal Formulations of Sorafenib Facilitate a Long-Acting Antitumor Effect and Relieve Treatment Side Effects as Observed With Fundus Microcirculation Imaging

The tyrosine kinase inhibitors (TKIs), including sorafenib, remain one first-line antitumor treatment strategy for advanced hepatocellular carcinoma (HCC). However, many problems exist with the current orally administered TKIs, creating a heavy medical burden and causing severe side effects. In this...

Full description

Bibliographic Details
Main Authors: Junxiao Wang, Rui Liu, Yun Zhao, Zhenhu Ma, Zejie Sang, Zhenyu Wen, Xueling Yang, Hui Xie
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-08-01
Series:Frontiers in Oncology
Subjects:
advanced hepatocellular carcinoma
novel sorafenib microcrystal
sustained release and long acting
fundus microcirculation imaging
molecular targeted agents
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.743055/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2021.743055/full

Similar Items